Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
OnKure Therapeutics, Inc. - Class A Common Stock
(NQ:
OKUR
)
3.100
-0.170 (-5.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about OnKure Therapeutics, Inc. - Class A Common Stock
OnKure Therapeutics Inc-A (NASDAQ:OKUR) Reports Q2 2025 Earnings Beat with Narrower-Than-Expected Loss
August 12, 2025
OnKure Therapeutics (OKUR) reported Q2 2025 EPS of -$1.14, beating estimates, with no revenue. Stock rose 1.5% after hours. Clinical progress on OKI-219 cancer drug remains on track for Q4 2025 data.
Via
Chartmill
Topics
Earnings
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
March 11, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 17, 2025
Via
Benzinga
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
October 10, 2024
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting...
Via
Benzinga
This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 10, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today